Open AccessProtection against murine tuberculosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the 30‐kDa antigen of Mycobacterium bovis BCG
Author(s) -
Hess Jürgen,
Grode Leander,
Hellwig Jacqueline,
Conradt Peter,
Gentschev Ivo,
Goebel Werner,
Ladel Christoph,
Kaufmann Stefan H.E.
Publication year - 2000
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2000.tb01441.x
Subject(s) - microbiology and biotechnology , mycobacterium bovis , biology , mycobacterium tuberculosis , salmonella , immune system , antigen , virology , recombinant dna , aroa , attenuated vaccine , vaccination , splenocyte , tuberculosis , enterobacteriaceae , immunology , bacteria , virulence , escherichia coli , medicine , biochemistry , genetics , pathology , gene
A recombinant (r‐) Salmonella typhimurium aroA vaccine that secretes the naturally secreted protein of Mycobacterium bovis strain BCG, Ag85B, by means of the HlyB/HlyD/TolC export machinery (termed p30 in the following) was constructed. In contrast to r‐ S. typhimurium control, oral vaccination of mice with the r‐ S. typhimurium p30 construct induced partial protection against an intravenous challenge with the intracellular pathogen Mycobacterium tuberculosis , resulting in similar vaccine efficacy comparable to that of the systemically administered attenuated M. bovis BCG strain. The immune response induced by r‐ S. typhimurium p30 was accompanied by augmented interferon‐γ (IFN‐γ) and tumor necrosis factor‐α (TNF‐α) levels produced by restimulated splenocytes. These data suggest that the HlyB/HlyD/TolC‐based antigen delivery system with attenuated r‐ S. typhimurium as carrier is capable of inducing an immune response against mycobacterial antigens.